Cancer News - Topix
Genzyme Corp , which is fighting off a hostile $18.5 billion bid from Sanofi-Aventis SA , will on Monday take another stab at persuading investors that its experimental multiple sclerosis drug is worth more than Sanofi's projections.
Sent with Reeder
Sent from my iPad
No comments:
Post a Comment